Precision Medicine in Oncology®

Dr. Debu Tripathy from USC Norris Cancer Center on Completing New Assays After Recurrence

Biomarkers offer great potential for improving management of cancer at every point from screening and detection, to diagnosis, staging, prognosis, and the assessment of treatment response.

Dr. Antonio C. Wolff from Sidney Kimmel Comprehensive Cancer Center Discusses the Importance of HER2 Testing

Dr. Debu Tripathy from USC Norris Cancer Center on the Oncotype DX Assay Recurrence Score

Dr. Debu Tripathy from USC Norris Cancer Center Discusses Breast Cancer Gene Profiling

Dr. Debu Tripathy from the USC Norris Comphrensive Cancer Center Discusses Breast Cancer Biomarkers

Amid a continuing emphasis on targeted therapies, pharmaceutical companies have approximately 300 drugs in phase II or later-stage development for cancer treatment.

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses Available Targeted Therapies

As personalized medicine occupies a growing role in the pharmaceutical pipeline, major companies are changing their research and development paradigms.

The oncology community is quite conversant with the clinical utility of prognostic tumor markers.

In the context of caring for cancer patients, all physicians and nurses trained in oncology receive education in quality-of-life issues; however, prolonging quantity of life remains our ultimate goal.

Previously unknown genetic methylation patterns and new mutations for squamous cell carcinoma of the head and neck discovered.

PFS improved significantly in patients with EGFR-mutated advanced NSCLC treated first line with erlotinib versus platinum-based chemotherapy.

Dr. Jack West from the Swedish Cancer Institute Talks About Anticipated Future Clinical Trials

When Robert A. Weinberg was a boy, he loved dissecting what was complicated and figuring out what made it work.

Amid growing cost pressures in the pharmaceutical industry, many small companies are playing an increasingly active role in drug development.

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center on How the Institutes in the mutlicenter study examining driver mutations Worked Together

Add-on therapy with an inhibitor of the MET signaling pathway significantly improved PFS and OS in patients with MET-positive NSCLC confirmed by immunohistochemistry.

Dr. Jack West from Swedish Cancer Institute Discusses 4 Important Upcoming Clinical Trials Results in Lung Cancer.

Dr. Apostolia Tsimberidou from MD Anderson Cancer Center on the Next Steps for Personalized Care

Intense research has resulted in JAK-STAT becoming one of the best-understood signal transduction cascades.

Srdan Verstovsek, MD, PhD, is a medical oncologist and associate professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston.

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses the Field of Mutation Testing

Dr. Axel Hoos medical lead at Bristol-Myers Squibb on Why Melanoma is Amenable to Immunotherapy

Findings from a randomized phase III trial in China suggest erlotinib is suitable for first-line treatment in patients with EGFR mutation-positive NSCLC.